Search
Sunvozertinib
go.drugbank.com/drugs/DB18925Investigational[L53488] EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCLCs). … Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: 2-Propenamide, N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1- methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]-, N-{5-[(4-{[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino}pyrimidin-2-yl)amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl}prop-2-enamideRupatadine
go.drugbank.com/drugs/DB11614ApprovedInvestigationalRupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: RUPAFIN® 10 MG, RUPAFİN 1 MG / ML ORAL ÇÖZELTİ, 120 MLAfatinib
go.drugbank.com/drugs/DB08916ApprovedInvestigationalAfatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. … Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim [L2939].
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: GIOTRIF® 30 MG, GIOTRIF® 40 MGEtretinate
go.drugbank.com/drugs/DB00926ApprovedWithdrawnEtretinate is a medication used to treat severe psoriasis. It is a synthetic aromatic retinoid. … It is thought to bind to the retinoic acid receptors. Etretinate is also believed to enhance the binding of cAMP to the regulatory RI subunit of cAMP dependent protein kinases.
Calcifediol
go.drugbank.com/drugs/DB00146ApprovedInvestigationalNutraceuticalIt is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients.
Mixtures: HEPATAMINE %8 500 ML(SETLI), HEPATAMINE %8 500 ML(SETSIZ)Categories: Vitamin D and AnaloguesAlizapride
go.drugbank.com/drugs/DB01425InvestigationalAlizapride is a dopamine antagonist that is capable of demonstrating both prokinetic and antiemetic effects.
Categories: Heterocyclic Compounds, 1-RingProducts: ALIPRID ®, PLITICAN® GOTASAmsacrine
go.drugbank.com/drugs/DB00276ApprovedInvestigationalWithdrawnAminoacridine derivative that is a potent intercalating antineoplastic agent. … It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors.
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 3-RingSynonyms: 4'-(9-Acridinylamino)-3'-methoxymethanesulfonanilide, 4'-(9-Acridinylamino)methanesulfon-m-anisidideBinodenoson
go.drugbank.com/drugs/DB04853InvestigationalBinodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor. … This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion
Synonyms: 2-((Cyclohexylmethylene)hydrazino)adenosineCategories: Heterocyclic Compounds, 2-RingSalmon calcitonin
go.drugbank.com/drugs/DB00017ApprovedInvestigationalSynthetic peptide, 32 residues long formulated as a nasal spray.
Products: MIACALCIC 100 IU AMPUL, 5 ADETGedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigationalGedatolisib is a kinase inhibitor that blocks all four class I PI3K isoforms together with both mTOR complexes, mTORC1 and mTORC2, producing downstream inhibition of multiple effectors including AKT. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors, Heterocyclic Compounds, 1-Ring